nodes	percent_of_prediction	percent_of_DWPC	metapath
Docetaxel—ABCC10—Methotrexate—psoriatic arthritis	0.113	0.147	CbGbCtD
Docetaxel—CYP1B1—Dexamethasone—psoriatic arthritis	0.0765	0.0991	CbGbCtD
Docetaxel—SLCO1B3—Methotrexate—psoriatic arthritis	0.0632	0.0818	CbGbCtD
Docetaxel—SLC22A7—Methotrexate—psoriatic arthritis	0.0556	0.072	CbGbCtD
Docetaxel—ABCC1—Methotrexate—psoriatic arthritis	0.0437	0.0566	CbGbCtD
Docetaxel—ABCC2—Dexamethasone—psoriatic arthritis	0.0402	0.0521	CbGbCtD
Docetaxel—ABCG2—Dexamethasone—psoriatic arthritis	0.0364	0.0471	CbGbCtD
Docetaxel—ABCB1—Methylprednisolone—psoriatic arthritis	0.0347	0.0449	CbGbCtD
Docetaxel—ABCC2—Methotrexate—psoriatic arthritis	0.0323	0.0419	CbGbCtD
Docetaxel—ABCG2—Methotrexate—psoriatic arthritis	0.0292	0.0379	CbGbCtD
Docetaxel—CYP3A7—Dexamethasone—psoriatic arthritis	0.0269	0.0348	CbGbCtD
Docetaxel—CYP3A7-CYP3A51P—Dexamethasone—psoriatic arthritis	0.0269	0.0348	CbGbCtD
Docetaxel—ABCB1—Betamethasone—psoriatic arthritis	0.0226	0.0292	CbGbCtD
Docetaxel—ABCB1—Prednisolone—psoriatic arthritis	0.0223	0.0288	CbGbCtD
Docetaxel—ABCB1—Prednisone—psoriatic arthritis	0.021	0.0272	CbGbCtD
Docetaxel—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0208	0.0269	CbGbCtD
Docetaxel—CYP3A5—Dexamethasone—psoriatic arthritis	0.0202	0.0261	CbGbCtD
Docetaxel—CYP3A4—Triamcinolone—psoriatic arthritis	0.0158	0.0204	CbGbCtD
Docetaxel—CYP3A4—Betamethasone—psoriatic arthritis	0.0135	0.0175	CbGbCtD
Docetaxel—CYP3A4—Prednisolone—psoriatic arthritis	0.0133	0.0173	CbGbCtD
Docetaxel—ABCB1—Dexamethasone—psoriatic arthritis	0.0131	0.017	CbGbCtD
Docetaxel—CYP3A4—Prednisone—psoriatic arthritis	0.0126	0.0163	CbGbCtD
Docetaxel—ABCB1—Methotrexate—psoriatic arthritis	0.0105	0.0137	CbGbCtD
Docetaxel—CYP3A4—Dexamethasone—psoriatic arthritis	0.00786	0.0102	CbGbCtD
Docetaxel—BCL2—Inflammasomes—MEFV—psoriatic arthritis	0.000711	0.124	CbGpPWpGaD
Docetaxel—KIF11—tendon—psoriatic arthritis	0.00051	0.136	CbGeAlD
Docetaxel—BCL2—IL2 signaling events mediated by STAT5—LTA—psoriatic arthritis	0.00047	0.0822	CbGpPWpGaD
Docetaxel—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—MEFV—psoriatic arthritis	0.000342	0.0597	CbGpPWpGaD
Docetaxel—MAP4—skin of body—psoriatic arthritis	0.000309	0.0821	CbGeAlD
Docetaxel—BCL2—ATF-2 transcription factor network—IL23A—psoriatic arthritis	0.000299	0.0523	CbGpPWpGaD
Docetaxel—MAPT—tendon—psoriatic arthritis	0.000299	0.0795	CbGeAlD
Docetaxel—BCL2—skin of body—psoriatic arthritis	0.000281	0.0746	CbGeAlD
Docetaxel—Myalgia—Triamcinolone—psoriatic arthritis	0.000238	0.00109	CcSEcCtD
Docetaxel—Pneumonia—Methotrexate—psoriatic arthritis	0.000237	0.00109	CcSEcCtD
Docetaxel—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000237	0.00109	CcSEcCtD
Docetaxel—Myalgia—Methylprednisolone—psoriatic arthritis	0.000237	0.00109	CcSEcCtD
Docetaxel—Eye disorder—Prednisone—psoriatic arthritis	0.000237	0.00109	CcSEcCtD
Docetaxel—Infestation NOS—Methotrexate—psoriatic arthritis	0.000236	0.00108	CcSEcCtD
Docetaxel—Infestation—Methotrexate—psoriatic arthritis	0.000236	0.00108	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000235	0.00108	CcSEcCtD
Docetaxel—MAP4—tendon—psoriatic arthritis	0.000235	0.0625	CbGeAlD
Docetaxel—Flushing—Prednisone—psoriatic arthritis	0.000235	0.00108	CcSEcCtD
Docetaxel—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.000234	0.00107	CcSEcCtD
Docetaxel—Dry mouth—Triamcinolone—psoriatic arthritis	0.000232	0.00107	CcSEcCtD
Docetaxel—Renal failure—Methotrexate—psoriatic arthritis	0.000232	0.00106	CcSEcCtD
Docetaxel—Stomatitis—Methotrexate—psoriatic arthritis	0.00023	0.00105	CcSEcCtD
Docetaxel—Angiopathy—Prednisone—psoriatic arthritis	0.00023	0.00105	CcSEcCtD
Docetaxel—Conjunctivitis—Methotrexate—psoriatic arthritis	0.000229	0.00105	CcSEcCtD
Docetaxel—Confusional state—Methylprednisolone—psoriatic arthritis	0.000229	0.00105	CcSEcCtD
Docetaxel—Immune system disorder—Prednisone—psoriatic arthritis	0.000229	0.00105	CcSEcCtD
Docetaxel—Oedema—Triamcinolone—psoriatic arthritis	0.000228	0.00104	CcSEcCtD
Docetaxel—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.000228	0.00104	CcSEcCtD
Docetaxel—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.000227	0.00104	CcSEcCtD
Docetaxel—Syncope—Dexamethasone—psoriatic arthritis	0.000227	0.00104	CcSEcCtD
Docetaxel—Syncope—Betamethasone—psoriatic arthritis	0.000227	0.00104	CcSEcCtD
Docetaxel—Arrhythmia—Prednisone—psoriatic arthritis	0.000226	0.00104	CcSEcCtD
Docetaxel—Infection—Triamcinolone—psoriatic arthritis	0.000226	0.00104	CcSEcCtD
Docetaxel—Infection—Methylprednisolone—psoriatic arthritis	0.000226	0.00104	CcSEcCtD
Docetaxel—Shock—Triamcinolone—psoriatic arthritis	0.000224	0.00103	CcSEcCtD
Docetaxel—Insomnia—Prednisolone—psoriatic arthritis	0.000224	0.00103	CcSEcCtD
Docetaxel—Alopecia—Prednisone—psoriatic arthritis	0.000224	0.00103	CcSEcCtD
Docetaxel—Shock—Methylprednisolone—psoriatic arthritis	0.000224	0.00103	CcSEcCtD
Docetaxel—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000223	0.00102	CcSEcCtD
Docetaxel—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000223	0.00102	CcSEcCtD
Docetaxel—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000223	0.00102	CcSEcCtD
Docetaxel—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000223	0.00102	CcSEcCtD
Docetaxel—Epistaxis—Methotrexate—psoriatic arthritis	0.000222	0.00102	CcSEcCtD
Docetaxel—Paraesthesia—Prednisolone—psoriatic arthritis	0.000222	0.00102	CcSEcCtD
Docetaxel—Tachycardia—Triamcinolone—psoriatic arthritis	0.000222	0.00102	CcSEcCtD
Docetaxel—Mental disorder—Prednisone—psoriatic arthritis	0.000222	0.00102	CcSEcCtD
Docetaxel—Tachycardia—Methylprednisolone—psoriatic arthritis	0.000222	0.00102	CcSEcCtD
Docetaxel—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000221	0.00101	CcSEcCtD
Docetaxel—Malnutrition—Prednisone—psoriatic arthritis	0.000221	0.00101	CcSEcCtD
Docetaxel—Erythema—Prednisone—psoriatic arthritis	0.000221	0.00101	CcSEcCtD
Docetaxel—Agranulocytosis—Methotrexate—psoriatic arthritis	0.00022	0.00101	CcSEcCtD
Docetaxel—Convulsion—Betamethasone—psoriatic arthritis	0.000219	0.00101	CcSEcCtD
Docetaxel—Convulsion—Dexamethasone—psoriatic arthritis	0.000219	0.00101	CcSEcCtD
Docetaxel—Hypertension—Dexamethasone—psoriatic arthritis	0.000219	0.001	CcSEcCtD
Docetaxel—Hypertension—Betamethasone—psoriatic arthritis	0.000219	0.001	CcSEcCtD
Docetaxel—Myalgia—Betamethasone—psoriatic arthritis	0.000216	0.000989	CcSEcCtD
Docetaxel—Myalgia—Dexamethasone—psoriatic arthritis	0.000216	0.000989	CcSEcCtD
Docetaxel—Haemoglobin—Methotrexate—psoriatic arthritis	0.000213	0.000976	CcSEcCtD
Docetaxel—Hypotension—Methylprednisolone—psoriatic arthritis	0.000212	0.000974	CcSEcCtD
Docetaxel—Pain—Prednisolone—psoriatic arthritis	0.000212	0.000971	CcSEcCtD
Docetaxel—Haemorrhage—Methotrexate—psoriatic arthritis	0.000212	0.000971	CcSEcCtD
Docetaxel—Hepatitis—Methotrexate—psoriatic arthritis	0.000212	0.000971	CcSEcCtD
Docetaxel—Pharyngitis—Methotrexate—psoriatic arthritis	0.00021	0.000964	CcSEcCtD
Docetaxel—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000209	0.000959	CcSEcCtD
Docetaxel—Urethral disorder—Methotrexate—psoriatic arthritis	0.000208	0.000952	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.000208	0.000952	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000207	0.00095	CcSEcCtD
Docetaxel—Oedema—Betamethasone—psoriatic arthritis	0.000207	0.000948	CcSEcCtD
Docetaxel—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000207	0.000948	CcSEcCtD
Docetaxel—Oedema—Dexamethasone—psoriatic arthritis	0.000207	0.000948	CcSEcCtD
Docetaxel—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000207	0.000948	CcSEcCtD
Docetaxel—BCL2—Apoptosis—LTA—psoriatic arthritis	0.000206	0.0361	CbGpPWpGaD
Docetaxel—Insomnia—Triamcinolone—psoriatic arthritis	0.000206	0.000945	CcSEcCtD
Docetaxel—Insomnia—Methylprednisolone—psoriatic arthritis	0.000206	0.000943	CcSEcCtD
Docetaxel—Infection—Dexamethasone—psoriatic arthritis	0.000205	0.000942	CcSEcCtD
Docetaxel—Infection—Betamethasone—psoriatic arthritis	0.000205	0.000942	CcSEcCtD
Docetaxel—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000205	0.000938	CcSEcCtD
Docetaxel—Feeling abnormal—Prednisolone—psoriatic arthritis	0.000204	0.000936	CcSEcCtD
Docetaxel—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000204	0.000936	CcSEcCtD
Docetaxel—Visual impairment—Methotrexate—psoriatic arthritis	0.000204	0.000936	CcSEcCtD
Docetaxel—Anaemia—Prednisone—psoriatic arthritis	0.000204	0.000935	CcSEcCtD
Docetaxel—Shock—Dexamethasone—psoriatic arthritis	0.000203	0.000932	CcSEcCtD
Docetaxel—Shock—Betamethasone—psoriatic arthritis	0.000203	0.000932	CcSEcCtD
Docetaxel—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000203	0.000931	CcSEcCtD
Docetaxel—MAP2—SIDS Susceptibility Pathways—IL13—psoriatic arthritis	0.000203	0.0355	CbGpPWpGaD
Docetaxel—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000203	0.000929	CcSEcCtD
Docetaxel—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000203	0.000929	CcSEcCtD
Docetaxel—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000202	0.000928	CcSEcCtD
Docetaxel—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000202	0.000928	CcSEcCtD
Docetaxel—Tachycardia—Betamethasone—psoriatic arthritis	0.000202	0.000925	CcSEcCtD
Docetaxel—Tachycardia—Dexamethasone—psoriatic arthritis	0.000202	0.000925	CcSEcCtD
Docetaxel—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000201	0.000919	CcSEcCtD
Docetaxel—Erythema multiforme—Methotrexate—psoriatic arthritis	0.0002	0.000918	CcSEcCtD
Docetaxel—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.0002	0.000917	CcSEcCtD
Docetaxel—BCL2—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000198	0.0346	CbGpPWpGaD
Docetaxel—Eye disorder—Methotrexate—psoriatic arthritis	0.000198	0.000907	CcSEcCtD
Docetaxel—Syncope—Prednisone—psoriatic arthritis	0.000198	0.000907	CcSEcCtD
Docetaxel—Anorexia—Dexamethasone—psoriatic arthritis	0.000197	0.000903	CcSEcCtD
Docetaxel—Anorexia—Betamethasone—psoriatic arthritis	0.000197	0.000903	CcSEcCtD
Docetaxel—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000197	0.000901	CcSEcCtD
Docetaxel—Fatigue—Triamcinolone—psoriatic arthritis	0.000196	0.000901	CcSEcCtD
Docetaxel—Fatigue—Methylprednisolone—psoriatic arthritis	0.000196	0.000899	CcSEcCtD
Docetaxel—Pain—Triamcinolone—psoriatic arthritis	0.000195	0.000893	CcSEcCtD
Docetaxel—Loss of consciousness—Prednisone—psoriatic arthritis	0.000194	0.000889	CcSEcCtD
Docetaxel—Hypotension—Dexamethasone—psoriatic arthritis	0.000193	0.000886	CcSEcCtD
Docetaxel—Hypotension—Betamethasone—psoriatic arthritis	0.000193	0.000886	CcSEcCtD
Docetaxel—Angiopathy—Methotrexate—psoriatic arthritis	0.000192	0.000881	CcSEcCtD
Docetaxel—Immune system disorder—Methotrexate—psoriatic arthritis	0.000191	0.000877	CcSEcCtD
Docetaxel—Convulsion—Prednisone—psoriatic arthritis	0.000191	0.000876	CcSEcCtD
Docetaxel—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000191	0.000875	CcSEcCtD
Docetaxel—Hypertension—Prednisone—psoriatic arthritis	0.00019	0.000873	CcSEcCtD
Docetaxel—Chills—Methotrexate—psoriatic arthritis	0.00019	0.000871	CcSEcCtD
Docetaxel—KIF11—MHC class II antigen presentation—HLA-DRB1—psoriatic arthritis	0.00019	0.0331	CbGpPWpGaD
Docetaxel—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000188	0.000864	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000188	0.000864	CcSEcCtD
Docetaxel—TUBB4A—skin of body—psoriatic arthritis	0.000188	0.0499	CbGeAlD
Docetaxel—Arthralgia—Prednisone—psoriatic arthritis	0.000188	0.000861	CcSEcCtD
Docetaxel—Myalgia—Prednisone—psoriatic arthritis	0.000188	0.000861	CcSEcCtD
Docetaxel—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.000188	0.000861	CcSEcCtD
Docetaxel—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.000187	0.000859	CcSEcCtD
Docetaxel—Alopecia—Methotrexate—psoriatic arthritis	0.000187	0.000858	CcSEcCtD
Docetaxel—Insomnia—Dexamethasone—psoriatic arthritis	0.000187	0.000857	CcSEcCtD
Docetaxel—Insomnia—Betamethasone—psoriatic arthritis	0.000187	0.000857	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000186	0.000855	CcSEcCtD
Docetaxel—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000186	0.000852	CcSEcCtD
Docetaxel—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000186	0.000851	CcSEcCtD
Docetaxel—Paraesthesia—Betamethasone—psoriatic arthritis	0.000186	0.000851	CcSEcCtD
Docetaxel—Mental disorder—Methotrexate—psoriatic arthritis	0.000186	0.000851	CcSEcCtD
Docetaxel—MAP2—tendon—psoriatic arthritis	0.000185	0.0492	CbGeAlD
Docetaxel—Malnutrition—Methotrexate—psoriatic arthritis	0.000184	0.000845	CcSEcCtD
Docetaxel—Erythema—Methotrexate—psoriatic arthritis	0.000184	0.000845	CcSEcCtD
Docetaxel—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000183	0.000837	CcSEcCtD
Docetaxel—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000182	0.000834	CcSEcCtD
Docetaxel—Dyspepsia—Betamethasone—psoriatic arthritis	0.000182	0.000834	CcSEcCtD
Docetaxel—Dysgeusia—Methotrexate—psoriatic arthritis	0.000181	0.000828	CcSEcCtD
Docetaxel—Body temperature increased—Triamcinolone—psoriatic arthritis	0.00018	0.000826	CcSEcCtD
Docetaxel—Anaphylactic shock—Prednisone—psoriatic arthritis	0.00018	0.000825	CcSEcCtD
Docetaxel—Oedema—Prednisone—psoriatic arthritis	0.00018	0.000825	CcSEcCtD
Docetaxel—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.00018	0.000824	CcSEcCtD
Docetaxel—Decreased appetite—Dexamethasone—psoriatic arthritis	0.00018	0.000824	CcSEcCtD
Docetaxel—Decreased appetite—Betamethasone—psoriatic arthritis	0.00018	0.000824	CcSEcCtD
Docetaxel—Infection—Prednisone—psoriatic arthritis	0.000179	0.00082	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000178	0.000818	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000178	0.000818	CcSEcCtD
Docetaxel—Back pain—Methotrexate—psoriatic arthritis	0.000178	0.000818	CcSEcCtD
Docetaxel—Fatigue—Betamethasone—psoriatic arthritis	0.000178	0.000817	CcSEcCtD
Docetaxel—Fatigue—Dexamethasone—psoriatic arthritis	0.000178	0.000817	CcSEcCtD
Docetaxel—Shock—Prednisone—psoriatic arthritis	0.000177	0.000812	CcSEcCtD
Docetaxel—Pain—Betamethasone—psoriatic arthritis	0.000177	0.00081	CcSEcCtD
Docetaxel—Pain—Dexamethasone—psoriatic arthritis	0.000177	0.00081	CcSEcCtD
Docetaxel—Nervous system disorder—Prednisone—psoriatic arthritis	0.000177	0.000809	CcSEcCtD
Docetaxel—Tachycardia—Prednisone—psoriatic arthritis	0.000176	0.000806	CcSEcCtD
Docetaxel—Skin disorder—Prednisone—psoriatic arthritis	0.000175	0.000802	CcSEcCtD
Docetaxel—Anorexia—Prednisone—psoriatic arthritis	0.000172	0.000787	CcSEcCtD
Docetaxel—TUBB2A—skin of body—psoriatic arthritis	0.000171	0.0454	CbGeAlD
Docetaxel—Anaemia—Methotrexate—psoriatic arthritis	0.00017	0.000781	CcSEcCtD
Docetaxel—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.00017	0.000781	CcSEcCtD
Docetaxel—Feeling abnormal—Betamethasone—psoriatic arthritis	0.00017	0.000781	CcSEcCtD
Docetaxel—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000169	0.000775	CcSEcCtD
Docetaxel—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000169	0.000775	CcSEcCtD
Docetaxel—TUBB6—skin of body—psoriatic arthritis	0.000169	0.0448	CbGeAlD
Docetaxel—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000168	0.00077	CcSEcCtD
Docetaxel—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000167	0.000768	CcSEcCtD
Docetaxel—Leukopenia—Methotrexate—psoriatic arthritis	0.000165	0.000757	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000164	0.000752	CcSEcCtD
Docetaxel—Dizziness—Prednisolone—psoriatic arthritis	0.000164	0.000751	CcSEcCtD
Docetaxel—Asthenia—Triamcinolone—psoriatic arthritis	0.000163	0.000749	CcSEcCtD
Docetaxel—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000163	0.000749	CcSEcCtD
Docetaxel—Abdominal pain—Betamethasone—psoriatic arthritis	0.000163	0.000749	CcSEcCtD
Docetaxel—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000163	0.000749	CcSEcCtD
Docetaxel—Body temperature increased—Betamethasone—psoriatic arthritis	0.000163	0.000749	CcSEcCtD
Docetaxel—Asthenia—Methylprednisolone—psoriatic arthritis	0.000163	0.000748	CcSEcCtD
Docetaxel—Insomnia—Prednisone—psoriatic arthritis	0.000163	0.000747	CcSEcCtD
Docetaxel—Paraesthesia—Prednisone—psoriatic arthritis	0.000162	0.000741	CcSEcCtD
Docetaxel—Pruritus—Triamcinolone—psoriatic arthritis	0.000161	0.000739	CcSEcCtD
Docetaxel—Cough—Methotrexate—psoriatic arthritis	0.000161	0.000738	CcSEcCtD
Docetaxel—Pruritus—Methylprednisolone—psoriatic arthritis	0.000161	0.000737	CcSEcCtD
Docetaxel—Convulsion—Methotrexate—psoriatic arthritis	0.00016	0.000732	CcSEcCtD
Docetaxel—Dyspepsia—Prednisone—psoriatic arthritis	0.000158	0.000727	CcSEcCtD
Docetaxel—Myalgia—Methotrexate—psoriatic arthritis	0.000157	0.00072	CcSEcCtD
Docetaxel—Chest pain—Methotrexate—psoriatic arthritis	0.000157	0.00072	CcSEcCtD
Docetaxel—Arthralgia—Methotrexate—psoriatic arthritis	0.000157	0.00072	CcSEcCtD
Docetaxel—Decreased appetite—Prednisone—psoriatic arthritis	0.000156	0.000718	CcSEcCtD
Docetaxel—Rash—Prednisolone—psoriatic arthritis	0.000156	0.000716	CcSEcCtD
Docetaxel—Dermatitis—Prednisolone—psoriatic arthritis	0.000156	0.000716	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000156	0.000715	CcSEcCtD
Docetaxel—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000156	0.000713	CcSEcCtD
Docetaxel—Fatigue—Prednisone—psoriatic arthritis	0.000155	0.000712	CcSEcCtD
Docetaxel—Headache—Prednisolone—psoriatic arthritis	0.000155	0.000712	CcSEcCtD
Docetaxel—Constipation—Prednisone—psoriatic arthritis	0.000154	0.000706	CcSEcCtD
Docetaxel—Confusional state—Methotrexate—psoriatic arthritis	0.000152	0.000696	CcSEcCtD
Docetaxel—Dizziness—Triamcinolone—psoriatic arthritis	0.000151	0.000691	CcSEcCtD
Docetaxel—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.00015	0.00069	CcSEcCtD
Docetaxel—Dizziness—Methylprednisolone—psoriatic arthritis	0.00015	0.000689	CcSEcCtD
Docetaxel—Infection—Methotrexate—psoriatic arthritis	0.000149	0.000685	CcSEcCtD
Docetaxel—Feeling abnormal—Prednisone—psoriatic arthritis	0.000148	0.00068	CcSEcCtD
Docetaxel—Asthenia—Betamethasone—psoriatic arthritis	0.000148	0.00068	CcSEcCtD
Docetaxel—Asthenia—Dexamethasone—psoriatic arthritis	0.000148	0.00068	CcSEcCtD
Docetaxel—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000148	0.000676	CcSEcCtD
Docetaxel—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000147	0.000675	CcSEcCtD
Docetaxel—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000147	0.000675	CcSEcCtD
Docetaxel—Nausea—Prednisolone—psoriatic arthritis	0.000147	0.000675	CcSEcCtD
Docetaxel—TUBB4B—skin of body—psoriatic arthritis	0.000147	0.039	CbGeAlD
Docetaxel—Pruritus—Dexamethasone—psoriatic arthritis	0.000146	0.000671	CcSEcCtD
Docetaxel—Pruritus—Betamethasone—psoriatic arthritis	0.000146	0.000671	CcSEcCtD
Docetaxel—Skin disorder—Methotrexate—psoriatic arthritis	0.000146	0.00067	CcSEcCtD
Docetaxel—Vomiting—Triamcinolone—psoriatic arthritis	0.000145	0.000664	CcSEcCtD
Docetaxel—Vomiting—Methylprednisolone—psoriatic arthritis	0.000145	0.000663	CcSEcCtD
Docetaxel—Rash—Triamcinolone—psoriatic arthritis	0.000144	0.000659	CcSEcCtD
Docetaxel—Dermatitis—Triamcinolone—psoriatic arthritis	0.000144	0.000658	CcSEcCtD
Docetaxel—Anorexia—Methotrexate—psoriatic arthritis	0.000143	0.000658	CcSEcCtD
Docetaxel—Rash—Methylprednisolone—psoriatic arthritis	0.000143	0.000657	CcSEcCtD
Docetaxel—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000143	0.000657	CcSEcCtD
Docetaxel—TUBB4A—tendon—psoriatic arthritis	0.000143	0.038	CbGeAlD
Docetaxel—Headache—Triamcinolone—psoriatic arthritis	0.000143	0.000654	CcSEcCtD
Docetaxel—Headache—Methylprednisolone—psoriatic arthritis	0.000142	0.000653	CcSEcCtD
Docetaxel—Abdominal pain—Prednisone—psoriatic arthritis	0.000142	0.000652	CcSEcCtD
Docetaxel—Body temperature increased—Prednisone—psoriatic arthritis	0.000142	0.000652	CcSEcCtD
Docetaxel—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000141	0.000648	CcSEcCtD
Docetaxel—Diarrhoea—Betamethasone—psoriatic arthritis	0.000141	0.000648	CcSEcCtD
Docetaxel—Hypotension—Methotrexate—psoriatic arthritis	0.000141	0.000645	CcSEcCtD
Docetaxel—TUBB2B—tendon—psoriatic arthritis	0.000138	0.0367	CbGeAlD
Docetaxel—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000137	0.000628	CcSEcCtD
Docetaxel—Dizziness—Betamethasone—psoriatic arthritis	0.000137	0.000627	CcSEcCtD
Docetaxel—Dizziness—Dexamethasone—psoriatic arthritis	0.000137	0.000627	CcSEcCtD
Docetaxel—Insomnia—Methotrexate—psoriatic arthritis	0.000136	0.000624	CcSEcCtD
Docetaxel—Nausea—Triamcinolone—psoriatic arthritis	0.000135	0.00062	CcSEcCtD
Docetaxel—Paraesthesia—Methotrexate—psoriatic arthritis	0.000135	0.000619	CcSEcCtD
Docetaxel—Nausea—Methylprednisolone—psoriatic arthritis	0.000135	0.000619	CcSEcCtD
Docetaxel—Dyspnoea—Methotrexate—psoriatic arthritis	0.000134	0.000615	CcSEcCtD
Docetaxel—Somnolence—Methotrexate—psoriatic arthritis	0.000134	0.000613	CcSEcCtD
Docetaxel—Hypersensitivity—Prednisone—psoriatic arthritis	0.000133	0.000608	CcSEcCtD
Docetaxel—Dyspepsia—Methotrexate—psoriatic arthritis	0.000132	0.000607	CcSEcCtD
Docetaxel—Vomiting—Betamethasone—psoriatic arthritis	0.000131	0.000603	CcSEcCtD
Docetaxel—Vomiting—Dexamethasone—psoriatic arthritis	0.000131	0.000603	CcSEcCtD
Docetaxel—TUBB—tendon—psoriatic arthritis	0.000131	0.0348	CbGeAlD
Docetaxel—Decreased appetite—Methotrexate—psoriatic arthritis	0.000131	0.0006	CcSEcCtD
Docetaxel—Rash—Dexamethasone—psoriatic arthritis	0.00013	0.000598	CcSEcCtD
Docetaxel—Rash—Betamethasone—psoriatic arthritis	0.00013	0.000598	CcSEcCtD
Docetaxel—TUBB2A—tendon—psoriatic arthritis	0.00013	0.0346	CbGeAlD
Docetaxel—Dermatitis—Betamethasone—psoriatic arthritis	0.00013	0.000597	CcSEcCtD
Docetaxel—Dermatitis—Dexamethasone—psoriatic arthritis	0.00013	0.000597	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00013	0.000596	CcSEcCtD
Docetaxel—Fatigue—Methotrexate—psoriatic arthritis	0.00013	0.000595	CcSEcCtD
Docetaxel—Headache—Betamethasone—psoriatic arthritis	0.000129	0.000594	CcSEcCtD
Docetaxel—Headache—Dexamethasone—psoriatic arthritis	0.000129	0.000594	CcSEcCtD
Docetaxel—Asthenia—Prednisone—psoriatic arthritis	0.000129	0.000592	CcSEcCtD
Docetaxel—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—psoriatic arthritis	0.000129	0.0225	CbGpPWpGaD
Docetaxel—Pain—Methotrexate—psoriatic arthritis	0.000129	0.00059	CcSEcCtD
Docetaxel—TUBB6—tendon—psoriatic arthritis	0.000128	0.0341	CbGeAlD
Docetaxel—Pruritus—Prednisone—psoriatic arthritis	0.000127	0.000584	CcSEcCtD
Docetaxel—Feeling abnormal—Methotrexate—psoriatic arthritis	0.000124	0.000568	CcSEcCtD
Docetaxel—Diarrhoea—Prednisone—psoriatic arthritis	0.000123	0.000565	CcSEcCtD
Docetaxel—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000123	0.000564	CcSEcCtD
Docetaxel—Nausea—Betamethasone—psoriatic arthritis	0.000123	0.000563	CcSEcCtD
Docetaxel—Nausea—Dexamethasone—psoriatic arthritis	0.000123	0.000563	CcSEcCtD
Docetaxel—Dizziness—Prednisone—psoriatic arthritis	0.000119	0.000546	CcSEcCtD
Docetaxel—Body temperature increased—Methotrexate—psoriatic arthritis	0.000119	0.000545	CcSEcCtD
Docetaxel—Abdominal pain—Methotrexate—psoriatic arthritis	0.000119	0.000545	CcSEcCtD
Docetaxel—BCL2—Apoptosis—TNFRSF1B—psoriatic arthritis	0.000119	0.0207	CbGpPWpGaD
Docetaxel—CYP1B1—skin of body—psoriatic arthritis	0.000116	0.0309	CbGeAlD
Docetaxel—Vomiting—Prednisone—psoriatic arthritis	0.000114	0.000525	CcSEcCtD
Docetaxel—Rash—Prednisone—psoriatic arthritis	0.000114	0.00052	CcSEcCtD
Docetaxel—Dermatitis—Prednisone—psoriatic arthritis	0.000113	0.00052	CcSEcCtD
Docetaxel—Headache—Prednisone—psoriatic arthritis	0.000113	0.000517	CcSEcCtD
Docetaxel—ABCC10—tendon—psoriatic arthritis	0.000112	0.0299	CbGeAlD
Docetaxel—TUBB4B—tendon—psoriatic arthritis	0.000112	0.0297	CbGeAlD
Docetaxel—BCL2—Apoptosis Modulation and Signaling—TNFRSF1B—psoriatic arthritis	0.000111	0.0194	CbGpPWpGaD
Docetaxel—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000111	0.000508	CcSEcCtD
Docetaxel—Asthenia—Methotrexate—psoriatic arthritis	0.000108	0.000495	CcSEcCtD
Docetaxel—KIF11—Immune System—MEFV—psoriatic arthritis	0.000108	0.0188	CbGpPWpGaD
Docetaxel—Nausea—Prednisone—psoriatic arthritis	0.000107	0.00049	CcSEcCtD
Docetaxel—Pruritus—Methotrexate—psoriatic arthritis	0.000106	0.000488	CcSEcCtD
Docetaxel—Diarrhoea—Methotrexate—psoriatic arthritis	0.000103	0.000472	CcSEcCtD
Docetaxel—Dizziness—Methotrexate—psoriatic arthritis	9.95e-05	0.000456	CcSEcCtD
Docetaxel—KIF11—Adaptive Immune System—REL—psoriatic arthritis	9.88e-05	0.0173	CbGpPWpGaD
Docetaxel—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	9.65e-05	0.0169	CbGpPWpGaD
Docetaxel—Vomiting—Methotrexate—psoriatic arthritis	9.57e-05	0.000439	CcSEcCtD
Docetaxel—Rash—Methotrexate—psoriatic arthritis	9.49e-05	0.000435	CcSEcCtD
Docetaxel—Dermatitis—Methotrexate—psoriatic arthritis	9.48e-05	0.000435	CcSEcCtD
Docetaxel—Headache—Methotrexate—psoriatic arthritis	9.43e-05	0.000432	CcSEcCtD
Docetaxel—EGFR—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	9.4e-05	0.0164	CbGpPWpGaD
Docetaxel—KIF11—Adaptive Immune System—HLA-C—psoriatic arthritis	9.09e-05	0.0159	CbGpPWpGaD
Docetaxel—ABCC2—tendon—psoriatic arthritis	9.03e-05	0.024	CbGeAlD
Docetaxel—BCL2—Overview of nanoparticle effects—TNF—psoriatic arthritis	8.98e-05	0.0157	CbGpPWpGaD
Docetaxel—Nausea—Methotrexate—psoriatic arthritis	8.94e-05	0.00041	CcSEcCtD
Docetaxel—CYP1B1—tendon—psoriatic arthritis	8.84e-05	0.0235	CbGeAlD
Docetaxel—ABCC1—tendon—psoriatic arthritis	7.95e-05	0.0211	CbGeAlD
Docetaxel—BCL2—ATF-2 transcription factor network—NOS2—psoriatic arthritis	7.31e-05	0.0128	CbGpPWpGaD
Docetaxel—BCL2—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriatic arthritis	6.99e-05	0.0122	CbGpPWpGaD
Docetaxel—KIF11—Immune System—REL—psoriatic arthritis	5.99e-05	0.0105	CbGpPWpGaD
Docetaxel—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—psoriatic arthritis	5.77e-05	0.0101	CbGpPWpGaD
Docetaxel—KIF11—Immune System—HLA-C—psoriatic arthritis	5.51e-05	0.00963	CbGpPWpGaD
Docetaxel—KIF11—Adaptive Immune System—HLA-B—psoriatic arthritis	5.38e-05	0.00939	CbGpPWpGaD
Docetaxel—BCL2—Amyotrophic lateral sclerosis (ALS)—TNF—psoriatic arthritis	5.16e-05	0.00901	CbGpPWpGaD
Docetaxel—KIF11—Hemostasis—NOS2—psoriatic arthritis	5.01e-05	0.00876	CbGpPWpGaD
Docetaxel—MAP2—SIDS Susceptibility Pathways—TNF—psoriatic arthritis	4.83e-05	0.00844	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—MEFV—psoriatic arthritis	4.83e-05	0.00844	CbGpPWpGaD
Docetaxel—BCL2—FAS pathway and Stress induction of HSP regulation—TNF—psoriatic arthritis	4.76e-05	0.00832	CbGpPWpGaD
Docetaxel—MAPT—Alzheimers Disease—TNF—psoriatic arthritis	4.67e-05	0.00816	CbGpPWpGaD
Docetaxel—KIF11—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	4.55e-05	0.00795	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	4.28e-05	0.00748	CbGpPWpGaD
Docetaxel—BCL2—Ceramide signaling pathway—TNF—psoriatic arthritis	4.28e-05	0.00747	CbGpPWpGaD
Docetaxel—KIF11—Immune System—NOD2—psoriatic arthritis	4.05e-05	0.00708	CbGpPWpGaD
Docetaxel—EGFR—AGE/RAGE pathway—NOS2—psoriatic arthritis	3.95e-05	0.0069	CbGpPWpGaD
Docetaxel—EGFR—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	3.9e-05	0.00682	CbGpPWpGaD
Docetaxel—EGFR—B Cell Activation—REL—psoriatic arthritis	3.78e-05	0.00661	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—HLA-C—psoriatic arthritis	3.76e-05	0.00657	CbGpPWpGaD
Docetaxel—BCL2—Caspase Cascade in Apoptosis—TNF—psoriatic arthritis	3.73e-05	0.00651	CbGpPWpGaD
Docetaxel—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	3.69e-05	0.00644	CbGpPWpGaD
Docetaxel—ABCB1—Allograft Rejection—HLA-C—psoriatic arthritis	3.62e-05	0.00633	CbGpPWpGaD
Docetaxel—ABCB1—Allograft Rejection—IL13—psoriatic arthritis	3.6e-05	0.00629	CbGpPWpGaD
Docetaxel—ABCB1—Allograft Rejection—IL17A—psoriatic arthritis	3.31e-05	0.00579	CbGpPWpGaD
Docetaxel—KIF11—Immune System—HLA-B—psoriatic arthritis	3.26e-05	0.0057	CbGpPWpGaD
Docetaxel—ABCB1—Allograft Rejection—IL12B—psoriatic arthritis	3.08e-05	0.00538	CbGpPWpGaD
Docetaxel—KIF11—Immune System—CRP—psoriatic arthritis	2.88e-05	0.00503	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—MEFV—psoriatic arthritis	2.86e-05	0.00499	CbGpPWpGaD
Docetaxel—BCL2—Immune System—MEFV—psoriatic arthritis	2.81e-05	0.00492	CbGpPWpGaD
Docetaxel—KIF11—Immune System—HLA-DRB1—psoriatic arthritis	2.76e-05	0.00482	CbGpPWpGaD
Docetaxel—BCL2—Apoptosis—TNF—psoriatic arthritis	2.73e-05	0.00478	CbGpPWpGaD
Docetaxel—MAPT—Apoptosis—TNF—psoriatic arthritis	2.72e-05	0.00476	CbGpPWpGaD
Docetaxel—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	2.68e-05	0.00469	CbGpPWpGaD
Docetaxel—CYP1B1—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	2.68e-05	0.00469	CbGpPWpGaD
Docetaxel—EGFR—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	2.62e-05	0.00457	CbGpPWpGaD
Docetaxel—EGFR—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	2.62e-05	0.00457	CbGpPWpGaD
Docetaxel—MAPT—MAPK Signaling Pathway—TNF—psoriatic arthritis	2.55e-05	0.00446	CbGpPWpGaD
Docetaxel—EGFR—Spinal Cord Injury—NOS2—psoriatic arthritis	2.48e-05	0.00433	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—HLA-C—psoriatic arthritis	2.47e-05	0.00432	CbGpPWpGaD
Docetaxel—TUBB6—Metabolism of proteins—ACE—psoriatic arthritis	2.33e-05	0.00406	CbGpPWpGaD
Docetaxel—TUBB2B—Metabolism of proteins—ACE—psoriatic arthritis	2.33e-05	0.00406	CbGpPWpGaD
Docetaxel—MAPT—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	2.3e-05	0.00403	CbGpPWpGaD
Docetaxel—TUBB3—Metabolism of proteins—ACE—psoriatic arthritis	2.25e-05	0.00393	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—HLA-B—psoriatic arthritis	2.23e-05	0.00389	CbGpPWpGaD
Docetaxel—TUBB2A—Metabolism of proteins—ACE—psoriatic arthritis	2.18e-05	0.0038	CbGpPWpGaD
Docetaxel—ABCB1—Allograft Rejection—HLA-B—psoriatic arthritis	2.14e-05	0.00374	CbGpPWpGaD
Docetaxel—TUBB1—Metabolism of proteins—ACE—psoriatic arthritis	2.13e-05	0.00372	CbGpPWpGaD
Docetaxel—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	1.99e-05	0.00348	CbGpPWpGaD
Docetaxel—TUBB4A—Metabolism of proteins—ACE—psoriatic arthritis	1.91e-05	0.00334	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—NOD2—psoriatic arthritis	1.82e-05	0.00318	CbGpPWpGaD
Docetaxel—ABCB1—Allograft Rejection—HLA-DRB1—psoriatic arthritis	1.81e-05	0.00317	CbGpPWpGaD
Docetaxel—TUBB4B—Metabolism of proteins—ACE—psoriatic arthritis	1.75e-05	0.00305	CbGpPWpGaD
Docetaxel—BCL2—Apoptosis—TNF—psoriatic arthritis	1.67e-05	0.00293	CbGpPWpGaD
Docetaxel—EGFR—Immune System—MEFV—psoriatic arthritis	1.66e-05	0.00291	CbGpPWpGaD
Docetaxel—BCL2—Immune System—REL—psoriatic arthritis	1.57e-05	0.00273	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—REL—psoriatic arthritis	1.53e-05	0.00267	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—HLA-B—psoriatic arthritis	1.46e-05	0.00255	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—HLA-C—psoriatic arthritis	1.46e-05	0.00255	CbGpPWpGaD
Docetaxel—BCL2—Immune System—HLA-C—psoriatic arthritis	1.44e-05	0.00252	CbGpPWpGaD
Docetaxel—BCL2—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	1.42e-05	0.00248	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—HLA-C—psoriatic arthritis	1.4e-05	0.00245	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—CRP—psoriatic arthritis	1.29e-05	0.00226	CbGpPWpGaD
Docetaxel—EGFR—Spinal Cord Injury—TNF—psoriatic arthritis	1.23e-05	0.00215	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—NOD2—psoriatic arthritis	1.08e-05	0.00188	CbGpPWpGaD
Docetaxel—BCL2—Immune System—NOD2—psoriatic arthritis	1.06e-05	0.00185	CbGpPWpGaD
Docetaxel—EGFR—MAPK Signaling Pathway—TNF—psoriatic arthritis	9.28e-06	0.00162	CbGpPWpGaD
Docetaxel—EGFR—Immune System—REL—psoriatic arthritis	9.25e-06	0.00162	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—HLA-B—psoriatic arthritis	8.65e-06	0.00151	CbGpPWpGaD
Docetaxel—ABCB1—Allograft Rejection—TNF—psoriatic arthritis	8.57e-06	0.0015	CbGpPWpGaD
Docetaxel—BCL2—Immune System—HLA-B—psoriatic arthritis	8.52e-06	0.00149	CbGpPWpGaD
Docetaxel—EGFR—Immune System—HLA-C—psoriatic arthritis	8.52e-06	0.00149	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	8.38e-06	0.00146	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—HLA-B—psoriatic arthritis	8.3e-06	0.00145	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—CRP—psoriatic arthritis	7.64e-06	0.00134	CbGpPWpGaD
Docetaxel—BCL2—Immune System—CRP—psoriatic arthritis	7.53e-06	0.00132	CbGpPWpGaD
Docetaxel—BCL2—Immune System—HLA-DRB1—psoriatic arthritis	7.21e-06	0.00126	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	7.03e-06	0.00123	CbGpPWpGaD
Docetaxel—EGFR—Immune System—NOD2—psoriatic arthritis	6.26e-06	0.00109	CbGpPWpGaD
Docetaxel—EGFR—Immune System—HLA-B—psoriatic arthritis	5.04e-06	0.00088	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CRP—psoriatic arthritis	4.45e-06	0.000778	CbGpPWpGaD
Docetaxel—EGFR—Immune System—HLA-DRB1—psoriatic arthritis	4.26e-06	0.000745	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	4.23e-06	0.000739	CbGpPWpGaD
Docetaxel—ABCC1—Disease—NOS2—psoriatic arthritis	3.98e-06	0.000695	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—TNF—psoriatic arthritis	3.92e-06	0.000684	CbGpPWpGaD
Docetaxel—EGFR—Disease—NOS2—psoriatic arthritis	3.75e-06	0.000655	CbGpPWpGaD
